Astellas Announces the Opening of Its New Gene Therapy Manufacturing Facility in North Carolina
Astellas Pharma Inc has announced the opening of a new late stage clinical and commercial manufacturing facility in Sanford, North Carolina, US. The facility will allow the company to expand its resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope.
The new 135,000 square-foot state-of-the-art gene therapy manufacturing facility located in Sanford, N.C., officially opened on June 8th. The facility will be good manufacturing practices (GMP) compliant and will support clinical and commercial scale manufacturing of Astellas’ adeno-associated virus (AAV) vectors for gene therapies.
Astellas has made $100 million investment in this new facility to support global supply chain needs and in-house quality control testing, in addition to creating more than 200 jobs through 2026. The new facility located at 6074 Enterprise Park Drive joins the vibrant biopharmaceutical research and manufacturing community established in Lee County.
About Astellas Gene Therapies
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients.